Nonalkolik steatohepatitte ursodeoksikolik asit tedavisi

Nonalkolik steatohepatit (NASH), serum transaminaz yüksekliği, karaciğer steatozu ve inflamasyonu ile karakterize, bazen fibrozis bulunan ve siroza ilerleyebilen bir hastalıktır. Potansiyel olarak ciddi olan bu hastalığın bilinen etkin bir tedavisi yoktur. Bu çalışmada hepatositoprotektif ve membran stabilizan etkisi bulunan ursodeoksikolik asit'in (UDCA) NASH tedavisindeki etkinliğini araştırdık. UDCA'I 16 hastaya 10 mg/kg/gün dozunda 6 ay süreyle verdik. Vakalar tedavi sonrası 6 ay takip edildi. Tedavi sonunda ortalama ALT, AST ve CGT düzeylerinde belirgin düşme oldu (p

Ursodeoxycholic acid treatment in nonalcoholic steatohepatitis

Nonalcoholic Steatohepatitis (NASH) is characteri-zed by elevated serum aminotransferase activities with hepatic steatosis, inflammation, and occasionally fibrosis that may progress ta cirrhosis. There is no proved treatment for this potentially serious disorder. We performed a study to investigate the efficacy of a hepatocytoprotective and membrane stabilizer agent, ursode-oxycholic acid (UDCA), in the treatment of NASH. Six-teen patients received 10 mg/kg/day UDCA for 6 months. The patients were followed 6 months after the treatment. The decreases in mean serum levels of ALT, AST and GGT were significant at the end of therapy (p

PDF

___

1. Ludvvig J, Viggiano TR, McCill DB, Oh B|. Nonalcoholic steatohepatitis: Mayo Clinic experiences vvith a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434-438.
2. Tetri BAN, Bacon BR. Nonalcoholic steatohepatitis. Med Clin N Am 1996; 80(5): 1147-1166.
3. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepa-titis.Ann Intern Med 1997;126:137-145.
4. Laurin ), Lindor KD, Crippin JS, Gossard A, Gores GJ, Lud-vvig ), et al. Ursodeoxycholic acid or clofibrate in the tre-atment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23:1464-1467.
5. Povvell EE, Cooksley WG, Hanson R, Searle ), Halliday JW, Povvell LW. The natural history of nonalcoholic steato-hepatitis: a follow-up study of forty-tvvo patients for ııp to 21 years. Hepatology 1990; 11:74-80.
6. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989: 20;594-598.
7. Itoh S, Yougel T, Kavvagoe K. Comparison betvveen nonal-coholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987;82:650-654.
8. Diehl AM, Goodman Z, Ishak KG. Alcohollike disease in nonalcoholics. A clinical and histologic comparison vvith alcohol-induced liver injury. Gastroenterology 1988; 95:1056-1062.
9. Pinto HC, Baptista A, Camilo ME, Valente A, Saragoca A, de Moura MC. Nonalcoholic steatohepatitis. Clinicopatho-logic comparison vvith alcoholic hepatitis in ambıılatory and hospitalized patients. Dig Dis Sci 1996; 41:172-179.
10. Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroente-rology 1994; 107:1103-1109.
11. Linder KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastro-enterology 1994; 106:1284-1290.
12. Heuman DM, Pandak WM, Hylemon PB, VVahlzevic ZR. Conjugates of ursodeoxycholate protect against cytoto-xicity of more hydrophobic bile salts. Hepatology 1991; 14:920-926.
13. Erlinger S. Hypercholeretic bile acids: a clue to mechanism? Hepatology 1990; 11:888-890.
14. Calmus Y, Gane P, Riuger P, Poupon R. Hepatic expres-sion of class I and class II majör histocompatibility complex molecules in primary biliary cirrhosis; effect of ursodeoxycholic acid. Hepatology 1990; 11:12-15.
15. Abdelmalek M, Ludvvig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. ) Clin Gastro-enterol 1995; 20:127-130.